Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 1.07
XNPT's Cash to Debt is ranked lower than
80% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. XNPT: 1.07 )
Ranked among companies with meaningful Cash to Debt only.
XNPT' s Cash to Debt Range Over the Past 10 Years
Min: 1.07  Med: 10000.00 Max: No Debt
Current: 1.07
Equity to Asset 0.05
XNPT's Equity to Asset is ranked lower than
91% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. XNPT: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
XNPT' s Equity to Asset Range Over the Past 10 Years
Min: -1.59  Med: 0.73 Max: 0.88
Current: 0.05
-1.59
0.88
F-Score: 2
Z-Score: -4.81
M-Score: -1.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -151.59
XNPT's Operating margin (%) is ranked lower than
57% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. XNPT: -151.59 )
Ranked among companies with meaningful Operating margin (%) only.
XNPT' s Operating margin (%) Range Over the Past 10 Years
Min: -2892.15  Med: -176.49 Max: 18.25
Current: -151.59
-2892.15
18.25
Net-margin (%) -158.59
XNPT's Net-margin (%) is ranked lower than
58% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. XNPT: -158.59 )
Ranked among companies with meaningful Net-margin (%) only.
XNPT' s Net-margin (%) Range Over the Past 10 Years
Min: -2864.5  Med: -171.24 Max: 24.77
Current: -158.59
-2864.5
24.77
ROE (%) -208.77
XNPT's ROE (%) is ranked lower than
93% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. XNPT: -208.77 )
Ranked among companies with meaningful ROE (%) only.
XNPT' s ROE (%) Range Over the Past 10 Years
Min: -147.73  Med: -60.68 Max: 27
Current: -208.77
-147.73
27
ROA (%) -42.57
XNPT's ROA (%) is ranked lower than
64% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. XNPT: -42.57 )
Ranked among companies with meaningful ROA (%) only.
XNPT' s ROA (%) Range Over the Past 10 Years
Min: -72.3  Med: -44.62 Max: 18.7
Current: -42.57
-72.3
18.7
ROC (Joel Greenblatt) (%) -3619.60
XNPT's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. XNPT: -3619.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XNPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3735.36  Med: -859.98 Max: 561.29
Current: -3619.6
-3735.36
561.29
Revenue Growth (3Y)(%) 5.90
XNPT's Revenue Growth (3Y)(%) is ranked higher than
54% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. XNPT: 5.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
XNPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.3  Med: -12.05 Max: 126.4
Current: 5.9
-72.3
126.4
EBITDA Growth (3Y)(%) 19.50
XNPT's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. XNPT: 19.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
XNPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.4  Med: -13.50 Max: 19.5
Current: 19.5
-53.4
19.5
EPS Growth (3Y)(%) 18.60
XNPT's EPS Growth (3Y)(%) is ranked higher than
75% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. XNPT: 18.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
XNPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.3  Med: -12.35 Max: 18.6
Current: 18.6
-52.3
18.6
» XNPT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

XNPT Guru Trades in Q2 2015

Jim Simons 173,936 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Charles Brandes Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2015

XNPT Guru Trades in Q3 2015

Paul Tudor Jones 109,200 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

XNPT Guru Trades in Q4 2015

Chuck Royce 690,200 sh (New)
PRIMECAP Management 91,000 sh (unchged)
Paul Tudor Jones 31,200 sh (-71.43%)
» More
Q1 2016

XNPT Guru Trades in Q1 2016

Chuck Royce 846,200 sh (+22.60%)
PRIMECAP Management 91,000 sh (unchged)
Paul Tudor Jones 13,300 sh (-57.37%)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:SPPI, NAS:OTIC, NAS:TLGT, NAS:AMRN, NAS:CLDX, NAS:MNKD, NAS:OMER, NAS:ACRS, OTCPK:PTCHF, NAS:GERN, NAS:MYOK, NAS:PGNX, NAS:ENTA, NAS:AGEN, NAS:VNDA, NAS:ARNA, NAS:SGMO, NAS:WVE, NAS:AIMT, NAS:LOXO » details
Traded in other countries:LMW.Germany,
XenoPort Inc is a biopharmaceutical company. It is engaged in developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders.

XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.

Ratios

vs
industry
vs
history
P/B 57.02
XNPT's P/B is ranked lower than
98% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. XNPT: 57.02 )
Ranked among companies with meaningful P/B only.
XNPT' s P/B Range Over the Past 10 Years
Min: 1.71  Med: 4.45 Max: 57.02
Current: 57.02
1.71
57.02
P/S 9.27
XNPT's P/S is ranked higher than
58% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. XNPT: 9.27 )
Ranked among companies with meaningful P/S only.
XNPT' s P/S Range Over the Past 10 Years
Min: 2.64  Med: 13.65 Max: 105.87
Current: 9.27
2.64
105.87
Current Ratio 7.58
XNPT's Current Ratio is ranked higher than
67% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. XNPT: 7.58 )
Ranked among companies with meaningful Current Ratio only.
XNPT' s Current Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.78 Max: 12.4
Current: 7.58
2.31
12.4
Quick Ratio 7.45
XNPT's Quick Ratio is ranked higher than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. XNPT: 7.45 )
Ranked among companies with meaningful Quick Ratio only.
XNPT' s Quick Ratio Range Over the Past 10 Years
Min: 2.31  Med: 7.78 Max: 12.28
Current: 7.45
2.31
12.28
Days Inventory 296.64
XNPT's Days Inventory is ranked lower than
84% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. XNPT: 296.64 )
Ranked among companies with meaningful Days Inventory only.
XNPT' s Days Inventory Range Over the Past 10 Years
Min: 196.85  Med: 237.06 Max: 271.98
Current: 296.64
196.85
271.98
Days Sales Outstanding 50.31
XNPT's Days Sales Outstanding is ranked higher than
60% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. XNPT: 50.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
XNPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.46  Med: 43.11 Max: 96.22
Current: 50.31
4.46
96.22
Days Payable 434.34
XNPT's Days Payable is ranked higher than
92% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. XNPT: 434.34 )
Ranked among companies with meaningful Days Payable only.
XNPT' s Days Payable Range Over the Past 10 Years
Min: 354.82  Med: 446.74 Max: 494.16
Current: 434.34
354.82
494.16

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 58.92
XNPT's Price/Tangible Book is ranked lower than
97% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. XNPT: 58.92 )
Ranked among companies with meaningful Price/Tangible Book only.
XNPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 4.51 Max: 36.37
Current: 58.92
1.8
36.37
Price/Median PS Value 0.68
XNPT's Price/Median PS Value is ranked higher than
72% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. XNPT: 0.68 )
Ranked among companies with meaningful Price/Median PS Value only.
XNPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.05 Max: 6.66
Current: 0.68
0.22
6.66
Earnings Yield (Greenblatt) (%) -16.40
XNPT's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. XNPT: -16.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XNPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -16.4  Med: 1.90 Max: 2.5
Current: -16.4
-16.4
2.5

More Statistics

Revenue (TTM) (Mil) $48.22
EPS (TTM) $ -1.20
Beta3.23
Short Percentage of Float11.35%
52-Week Range $3.35 - 7.86
Shares Outstanding (Mil)63.53

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17
Revenue (Mil $) 115 90
EPS ($) -0.06 -0.77
EPS w/o NRI ($) -0.06 -0.77
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for XNPT

Headlines

Articles On GuruFocus.com
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 
Weekly Top Insider Buys: Sovereign Bancorp Inc., Jefferies Group Inc., XenoPort Inc., Sandridge Ener May 24 2008 

More From Other Websites
XENOPORT INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Jul 05 2016
Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort Jul 05 2016
Arbor Pharmaceuticals Completes Successful Tender Offer for Shares of XenoPort Jul 05 2016
What Brexit Vote Could Mean for U.S. 2016 Election Jun 22 2016
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc.,... Jun 20 2016
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period Jun 16 2016
Arbor Pharmaceuticals and XenoPort Announce the Expiration of the HSR Act Waiting Period Jun 16 2016
Surging Earnings Estimates Signal Good News for Xenoport (XNPT) Jun 06 2016
SHAREHOLDER ALERT: Law Offices of Marc S. Henzel Announces Investigation into the proposed sales and... Jun 02 2016
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 27 2016
XENOPORT SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Xenoport, Inc.... May 26 2016
The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie May 26 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning Whether the Sale of... May 25 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of XenoPort, Inc.... May 24 2016
Xenoport Surges on Takeover Bid and Outperforms the Market May 24 2016
ETF’s with exposure to XenoPort, Inc. : May 24, 2016 May 24 2016
Arbor Pharmaceuticals to buy XenoPort for $467 million May 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)